William Harvey Research Limited was established in 1990 and offers a broad range of disease models to support studies in inflammation, cardiovascular disease, pain, diabetes, and transplant/immunology.

WHRL has been leading the way as a preclinical contract research organisation (CRO) for the pharmaceutical and biotechnology sectors for over 25 years. Offering more than 120 in vivo and in vitro disease models across therapeutic areas, our expert team of academics from the prestigious, world-renowned William Harvey Research Institute in London (the largest pharmacological research institute in the UK) provide bespoke study design, specialised advice, one-to-one discussions, comprehensive reports of research findings including full statistical analysis and interpretation of data, and long‐term collaboration with strategic partners.

We offer a pre-clinical drug evaluation service specialising in models of cardiovascular and inflammatory diseases such as myocardial ischemia, haemorrhagic shock, endotoxaemia also inflammatory bowel disease (IBD), neutrophil migration, pulmonary fibrosis, systemic lupus erthematosus (SLE), adjuvant arthritis, collagen II arthritis, EAE and many more; our team provides tailor made solutions for drug discovery.

We aim to provide our clients with a service which is efficient, reliable and of a high quality; offering advice prior to initiation of a study and a flexible experimental design helping to ensure that our client’s compound will be tested in the most appropriate model for achieving their desired outcomes.